Compare Illumina, Inc. (ILMN) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Carparts.Com Inc — how do they compare? Illumina, Inc. trades at $189.79 (market cap $27.94B), while Carparts.Com Inc trades at $4.89 (market cap $41.22M). The key difference: Illumina, Inc. is far larger — about 677.8× Carparts.Com Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Carparts.Com Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | PRTS | |
|---|---|---|
Market Cap | $27.94B | $41.22M |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $11.40 |
52-Week Low | $91.00 | $3.88 |
Enterprise Value | $29.33B | $56.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
PRTS trades at $4.97, down 6.23% today, following a 10:1 reverse stock split effective May 26, 2026, which helped it regain Nasdaq compliance. The company reported a Q1 2026 adjusted EBITDA beat and secured a $25 million credit facility in June 2026. Revenue has declined from $676M in 2023 to $548M in 2025, with net losses widening to -$50M. Analyst sentiment is positive with 60% buy ratings, but negative cash flow and profitability metrics highlight operational challenges.
The outlook remains cautious due to persistent losses and revenue contraction, though cost-cutting and new financing provide some stability. Investment opportunity lies in potential turnaround execution and low P/S of 0.06, but risks include cash burn, competitive pressures, and reliance on external funding. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
